A multicenter prospective cohort study to investigate the effectiveness and safety of apixaban in Japanese elderly atrial fibrillation patients (J-ELD AF Registry).
Ken OkumuraTakeshi YamashitaShinya SuzukiMasaharu Akaonull nullPublished in: Clinical cardiology (2019)
Incidences of stroke or systemic embolism and bleeding requiring hospitalization were similar between standard and reduced apixaban doses in the elderly NVAF patients. The incidences of total and cardiovascular death were significantly higher in the reduced dose group due to the coexisting higher risks in this group.
Keyphrases
- atrial fibrillation
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- venous thromboembolism
- left atrial
- catheter ablation
- heart failure
- left atrial appendage
- middle aged
- patient reported outcomes
- clinical trial
- acute coronary syndrome
- left ventricular
- community dwelling
- patient reported
- brain injury
- percutaneous coronary intervention
- subarachnoid hemorrhage